Faraday Pharmaceuticals

About:

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.

Website: http://faradaypharma.com/

Top Investors: Alexandria Real Estate Equities, Polaris Partners, OUP (Osage University Partners), ARCH Venture Partners, Washington Research Foundation

Description:

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

Total Funding Amount:

$141M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Seattle, Washington, United States

Founded Date:

2014-01-01

Contact Email:

info(AT)faradaypharma.com

Founders:

Christopher Toombs

Number of Employees:

1-10

Last Funding Date:

2022-11-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai